Anna Wald, MD
Infectious Disease · Seattle, WANPI 1679630115
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $99,544 of the $102,717 with a category attached, or 96.9%. 6 manufacturers reported payments, led by GSK at 53.2% of the total. Reporting peaked in 2021 at $29,731 and has fallen 57.6% since, to $12,606 in 2025. Among infectious disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $2703.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$55K
- Bayer Healthcare LLC$25K
- Merck$17K
- Gilead$6K
- Modernatx, Inc.$486
- Gen-probe, Inc.$80
Across 13 payments — averaging $31,301 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$262K
- Sanofi Pasteur Inc.$144K
What the payments were for
- Consulting fees$99,54497%
- Travel & lodging$2,1912%
- Food & beverage$9831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $54,668 |
| Bayer Healthcare LLC | 4 | $24,524 |
| Merck | 20 | $17,203 |
| Gilead | 5 | $5,757 |
| Modernatx, Inc. | 2 | $486 |
| Gen-probe, Inc. | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- V160$8,118
How this compares
$102,717 in reported general payments places this provider in the 95th percentile of 186 infectious disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Seattle
- Warren DingesSeattle$173K
- Paul DrainSeattle$149K
- Corey CasperSeattle$115K
- Jim BoonyaratanakornkitSeattle$62K
- Michael BoeckhSeattle$59K
- Jason GoldmanSeattle$58K
- Connie CelumSeattle$57K
- Hyang KimSeattle$51K
- Ferric FangSeattle$49K
- Heidi CraneSeattle$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.